Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

SOUTH SAN FRANCISCO, Calif., Jan. 12 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today provided a clinical update on voreloxin, its novel investigational drug candidate currently being developed in Phase 2 trials for acute myeloid leukemia (AML) and ovarian cancer. The clinical update coincides with the company's attendance at the 27th Annual JP Morgan Healthcare Conference in San Francisco.

"2008 was an important year for Sunesis, as we have continued to advance the development of voreloxin in both AML and ovarian cancer. We believe voreloxin has the potential to be a first-in-class anti-cancer agent for treating these diseases and potentially other hematologic and solid tumors," said Daniel Swisher, Chief Executive Officer and President of Sunesis. "We completed enrollment of our Phase 2 platinum-resistant ovarian cancer study and both of our ongoing AML studies are enrolling well, with 45 AML patients enrolled in the fourth quarter of 2008 alone. In the first half of 2009, we anticipate reporting additional data from all three of our ongoing voreloxin studies. We remain on track to initiate a pivotal voreloxin study in AML by the end of this year."

Sunesis is providing an update on the progress of its voreloxin clinical trials as follows:

Phase 2 and 1b/2 Studies of Voreloxin in AML

Sunesis is evaluating single agent voreloxin in an ongoing Phase 2 trial, known as REVEAL-1, in newly diagnosed elderly AML patients unlikely to benefit from standard induction chemotherapy. Interim results recently presented at the 50th Annual Meeting of the American Society of Hematology (ASH) show that voreloxin induces complete remissions in these poor risk patients. At ASH, outcome for the 29 patients enrolled and treated with Schedule A, 72 mg/m2 of vo
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq:   ... disease, announced today that the Company closed its ... Investment Management, Jack W. Schuler , Birchview ... were $10.5 million, before offering expenses.  The proceeds ...
(Date:12/24/2014)... December 23, 2014 GMO corn cases filed ... are in the process of being consolidated in a Kansas ... Re: Syngenta AG MIR 162 Corn Litigation, MDL No. 2591 ... , Management of the Syngenta GMO corn multidistrict litigation (MDL) ...
(Date:12/24/2014)... 23, 2014 On Friday, December 19, ... Omnibus and Continuing Resolution Appropriations Act of 2015, which ... to receive funding through the Congressionally Directed Medical Research ... The Hydrocephalus Association (HA), working in conjunction with its ...
(Date:12/24/2014)... Nashville Fertility Center announced that Dr. ... Society for Reproductive Medicine (ASRM), a leading professional organization committed ... his new role as treasurer, Dr. Hill also fills a ... in furthering the mission of ASRM. , Dr. Hill ...
Breaking Biology Technology:Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3Carey Danis & Lowe Reports on Syngenta GMO Corn Transfer Order 2Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3
... Xybion Medical ... its Research and Development facility in Fair Lawn, New Jersey. , ... Cedar Knolls, NJ (PRWEB) August 3, 2009 -- Xybion ... of Pristima™ the premier preclinical solution on the market, is pleased to announce that SK ...
... , , , ... Inc. (Nasdaq: GHDX ) today reported financial results and business progress ... revenue increased to $36.6 million in the second quarter of 2009 compared with ... Onco type DX(R) breast cancer test was $35.2 million in the second ...
... 4 /PRNewswire-Asia/ -- Shanghai ChemPartner Co., Ltd.,(ChemPartner) a wholly ... moved its drug discovery collaboration with ELARA,Pharmaceuticals to a ... the areas of DMPK, pharmacology and toxicology for ELARA,s ... from both sides will,work closely together to design and ...
Cached Biology Technology:SK Life Sciences has Licensed Pristima 2Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 2Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 3Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 4Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 5Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 6Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 7Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 8Genomic Health Announces Second Quarter 2009 Financial Results and Business Progress 9Shanghai ChemPartner and ELARA Pharmaceuticals Expand Drug Discovery Collaboration to a New Level 2
(Date:1/22/2015)... N.C. , Jan. 22, 2015 Infinisource has launched ... of the G2 model. The G2 sets a higher standard ... iSolved human capital management solution. With plug-and-play installation, touch screen ... time clock provides a robust time collection solution for the ...
(Date:12/22/2014)... Holiday Season may be the brightest ever for the ... long anticipated floodgates for consumer biometrics may finally be ... tablets, and wearable mobile devices that incorporate biometrics will ... nearly 4.8 billion biometric devices by 2020.   ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ...
Breaking Biology News(10 mins):Infinisource's NXG series sets new time clock standard 2First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3
... LAFAYETTE, Ind. - Proper and timely burning of some Eastern ... a wide range of species, a Purdue University report shows. ... nutrient from deep in the soil and depositing it on ... an important source of nutrition for a variety of species ...
... been a hot savanna region for at least the past ... hominids evolved in this areasays a team of researchers led ... findings may shed light on the evolutionary pressures that led ... develop a more slender physique, and sweat more copiously than ...
... , New Rochelle, NY, June 8, 2010The growing use ... may help individuals with diabetes optimize blood glucose control ... with diabetes, as described in a Special Supplement to ... published by Mary Ann Liebert, Inc. (http://www.liebertpub.com). The issue ...
Cached Biology News:Fire may be key to reviving dogwood trees in Eastern forests 2East-African human ancestors lived in hot environments, says Caltech-led team 2East-African human ancestors lived in hot environments, says Caltech-led team 3Importance of insulin delivery devices for diabetes management 2